Literature DB >> 15921829

Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.

Dan M Granoff1, Amy Morgan, Jo Anne Welsch.   

Abstract

BACKGROUND: One dose of a quadrivalent meningococcal conjugate (MC-4) vaccine elicits higher group C bactericidal responses in 2-year olds than a U.S.-licensed quadrivalent polysaccharide (MPS-4) vaccine [Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in 2-year olds by an investigational quadrivalent Neisseria meningitidis-diptheria toxoid conjugate vaccine. Pediatr Infect Dis J, 2004;23:490-7].
OBJECTIVE: Assess immunogenicity and persistence of serum antibody to capsular groups A, Y and W-135 in 2-year old children immunized with MC-4 vaccine.
DESIGN: Measurement of antibody responses in sera from a multicenter randomized trial comparing MC-4 and MPS-4 vaccines.
RESULTS: At 1 month, the group A serum bactericidal GMT was higher in the MC-4 than the MPS-4 group (P < 0.001) but there were no significant differences at 6 months. At 6 months, the respective Y and W-135 GMTs were higher in the MC-4 group (P < 0.05) but there were no differences at 1 month. The higher W-135 bactericidal titers reflected higher antibody avidity in the MC-4 group (P < 0.0001) and avidity maturation between 1 and 6 months (P < 0.05). At 2-year post-vaccination, the proportion of MC-4 immunized children with bactericidal titers > or =1:4 (presumed to be protective) was 15.0% (group A), 32.5% (group Y) and 45% (group W-135), as compared with 2.5, 15.4 and 17.5%, respectively, in unvaccinated children (P < 0.01 for group W-135; P < 0.05 for group A, and P = 0.07 for Y).
CONCLUSIONS: One dose of the MC-4 vaccine in 2-year olds elicits higher A, Y and W-135 bactericidal titers than MPS-4 vaccine. Compared with unvaccinated children, serum antibody titers remain elevated for 2 years after MC-4 vaccination. However, many vaccinated children have titers <1:4 and may require a booster dose for sustained protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921829     DOI: 10.1016/j.vaccine.2005.03.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Authors:  Shannon L Harris; How Tsao; Lindsey Ashton; David Goldblatt; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Authors:  George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

4.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

Review 5.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

Review 6.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

7.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.